UY38043A - Combinación farmacéutica que comprende tramadol clorhidrato de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor - Google Patents
Combinación farmacéutica que comprende tramadol clorhidrato de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolorInfo
- Publication number
- UY38043A UY38043A UY0001038043A UY38043A UY38043A UY 38043 A UY38043 A UY 38043A UY 0001038043 A UY0001038043 A UY 0001038043A UY 38043 A UY38043 A UY 38043A UY 38043 A UY38043 A UY 38043A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical combination
- hydroxylor
- pain treatment
- chloride
- immediate release
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 5
- 238000013265 extended release Methods 0.000 title abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 title abstract 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title 1
- 229960004380 tramadol Drugs 0.000 title 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 abstract 2
- 208000005298 acute pain Diseases 0.000 abstract 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 abstract 2
- 229960004945 etoricoxib Drugs 0.000 abstract 2
- 229960003107 tramadol hydrochloride Drugs 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Combinación farmacéutica que comprende: i) una primera formulación de tramadol clorhidrato de liberación extendida que contiene desde 2,0% a 12,0% p/p de tramadol clorhidrato, y ii) una segunda formulación de etoricoxib de liberación inmediata que contiene desde 6,0% a 18% p/p de etoricoxib, disolventes o vehículos; proceso de fabricación para preparar la combinación farmacéutica y las formulaciones individuales, donde la combinación se presenta en una dosificación única tal como, cápsulas, comprimidos, comprimidos en bicapa, granulados y sachets. La presente invención proporciona métodos para prevenir y tratar el dolor, tal como el dolor agudo, y el uso de la combinación farmacéutica para la prevención y el tratamiento del dolor, tal como el dolor agudo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2017/058519 WO2019130049A1 (en) | 2017-12-29 | 2017-12-29 | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38043A true UY38043A (es) | 2019-07-31 |
Family
ID=61024811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038043A UY38043A (es) | 2017-12-29 | 2018-12-28 | Combinación farmacéutica que comprende tramadol clorhidrato de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR114074A1 (es) |
| MX (1) | MX2018013070A (es) |
| UY (1) | UY38043A (es) |
| WO (1) | WO2019130049A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113521292A (zh) * | 2020-04-15 | 2021-10-22 | 江苏恒瑞医药股份有限公司 | 一种cox-2抑制剂和曲马多的复方制剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1207994B (it) | 1986-01-03 | 1989-06-01 | Therapicon Srl | Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche. |
| JP2002538176A (ja) | 1999-03-01 | 2002-11-12 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | トラマドール物質および選択的ｃｏｘ−２阻害薬を含んで成る組成物 |
| JP4425514B2 (ja) | 1999-11-29 | 2010-03-03 | メルク フロスト カナダ リミテツド | ５−クロロ−３−（４−メタンスルホニルフェニル）−６′−メチル−［２，３′］ビピリジニルの多形型、非晶質型および水和型 |
| PH12001001175B1 (en) | 2000-05-26 | 2006-08-10 | Merck Sharp & Dohme | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis |
| ES2376500T3 (es) | 2002-02-19 | 2012-03-14 | Adcock Ingram Limited | Combinaciones farmacéuticas de meloxicam, tramadol y paracetamol. |
| WO2005085199A1 (en) | 2004-01-14 | 2005-09-15 | Cadila Healthcare Limited | Novel polymorphs of etoricoxib |
| CN101237890A (zh) | 2005-06-10 | 2008-08-06 | 中外制药株式会社 | 含有葡甲胺的蛋白质制剂的稳定剂及其利用 |
| JP2009515956A (ja) | 2005-11-22 | 2009-04-16 | テバ ファーマシューティカル インダストリーズ リミティド | テルミサルタンの医薬組成物 |
| BRPI0700133A (pt) | 2007-01-29 | 2008-09-16 | Incrementha P D & I Pesquisa D | composição farmacêutica compreendendo tramadol e cetoprofeno em combinação |
| US20080026054A1 (en) | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
| EP2219633A2 (en) | 2007-11-23 | 2010-08-25 | Nectid, Inc. | Tapentadol compositions |
| EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
| CZ301299B6 (cs) | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| EP2281558A1 (en) | 2009-08-06 | 2011-02-09 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors |
| JP5399564B2 (ja) | 2009-10-16 | 2014-01-29 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | トラマドールとコキシブとの共結晶 |
| WO2012004677A1 (en) | 2010-07-05 | 2012-01-12 | Actavis Group Ptc Ehf | Solid state forms of etoricoxib salts |
| EP2601952A1 (en) | 2011-12-07 | 2013-06-12 | Zentiva, k.s. | Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
| PL2887924T3 (pl) | 2012-08-27 | 2017-09-29 | Cadila Healthcare Limited | Kompozycje farmaceutyczne etorykoksybu |
| WO2016015776A1 (en) | 2014-07-31 | 2016-02-04 | Krka, D.D., Novo Mesto | Pharmaceutical composition of etoricoxib |
| WO2016036588A1 (en) | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
| CN104586799A (zh) | 2015-01-07 | 2015-05-06 | 万全万特制药江苏有限公司 | 依托考昔分散片及其制备方法 |
| CN105343002B (zh) | 2015-11-27 | 2019-07-26 | 济南康和医药科技有限公司 | 一种依托考昔口服微乳制剂及其制备方法 |
| EP3238714A1 (en) * | 2016-04-28 | 2017-11-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Extended release formulations of flurbiprofen and tramadol |
| MX2016006464A (es) | 2016-05-18 | 2017-11-17 | Laboratorios Liomont S A De C V | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. |
-
2017
- 2017-12-29 WO PCT/IB2017/058519 patent/WO2019130049A1/en active Application Filing
- 2017-12-29 MX MX2018013070A patent/MX2018013070A/es unknown
-
2018
- 2018-12-28 UY UY0001038043A patent/UY38043A/es not_active Application Discontinuation
- 2018-12-28 AR ARP180103918A patent/AR114074A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019130049A1 (en) | 2019-07-04 |
| MX2018013070A (es) | 2019-10-15 |
| AR114074A1 (es) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18087352A (es) | Formulaciones de un inhibidor de lsd1 | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019002745A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
| CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
| UY38043A (es) | Combinación farmacéutica que comprende tramadol clorhidrato de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
| WO2020022976A3 (en) | A formulation comprising dexketoprofen | |
| UY37518A (es) | Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20231114 |